...
首页> 外文期刊>Journal of Ginseng Research >Subacute oral toxicity and bacterial mutagenicity study of Korean Red Ginseng oil
【24h】

Subacute oral toxicity and bacterial mutagenicity study of Korean Red Ginseng oil

机译:红参油的亚急性口服毒性和细菌致突变性研究

获取原文

摘要

Background Red ginseng oil (RGO) is produced by supercritical CO2 extraction of secondary products derived from Korean Red Ginseng extract. As the use of RGO has increased, product safety concerns have become more important. Methods In the present study, the subacute oral toxicity and bacterial reverse mutagenicity of RGO were evaluated. Sprague–Dawley rats were orally administered with RGO for 28 d by gavage. Daily RGO dose concentrations were 0?mg/kg body weight (bw), 500?mg/kg bw, 1,000?mg/kg bw, or 2,000?mg/kg bw per day. Bacterial reverse mutation tests included five bacterial strains ( Escherichia coli WP2 and Salmonella typhimurium TA98, TA100, TA1535, and TA1537), which were used in the presence or absence of metabolic activation. The plated incorporation method for mutation test was used with RGO concentrations ranging from 312.5?μg to 5,000?μg per plate. Results The subacute oral toxicity test results did not reveal any marked changes in clinical characteristics. There were no toxicological changes related to RGO administration in hematological and serum biochemical characteristics in either control or treatment animals. Furthermore, no gross or histopathological changes related to RGO treatment were observed. The bacterial reverse mutation test results did not reveal, at any RGO concentration level and in all bacterial strains, any increase in the number of revertant colonies in the RGO treatment group compared to that in the negative control group. Conclusion The no-observed-adverse-effect level of RGO is greater than 2,000?mg/kg bw and RGO did not induce genotoxicity related to bacterial reverse mutations.
机译:背景红参油(RGO)是通过超临界CO 2 萃取来自韩国红参提取物的副产品而产生的。随着RGO的使用增加,对产品安全的关注变得越来越重要。方法对RGO的亚急性口服毒性和细菌反向致突变性进行评估。通过管饲法对Sprague–Dawley大鼠口服RGO治疗28 d。每日RGO剂量浓度为每天0?mg / kg体重(bw),500?mg / kg bw,1,000?mg / kg bw或2,000?mg / kg bw。细菌反向突变测试包括五种细菌菌株(大肠杆菌WP2和鼠伤寒沙门氏菌TA98,TA100,TA1535和TA1537),它们在有或没有代谢激活的情况下使用。用于突变试验的平板掺入法使用的RGO浓度为每板312.5μg至5,000μg。结果亚急性口服毒性试验结果未显示临床特征有任何明显变化。在对照或治疗动物中,在血液学和血清生化特征方面,与RGO给药无关的毒理学变化。此外,未观察到与RGO治疗相关的总体或组织病理学改变。与阴性对照组相比,在任何RGO浓度水平和所有细菌菌株中,细菌反向突变测试结果均未显示RGO治疗组的回复菌落数量有任何增加。结论RGO的未观察到的不良反应水平大于2,000?mg / kg bw,RGO没有引起与细菌反向突变有关的遗传毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号